Alkermes (ALKS) Competitors $27.91 +0.43 (+1.56%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALKS vs. EIDX, AGIO, OPK, PCRX, AVIR, UTHR, INCY, NBIX, BMRN, and EXELShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Eidos Therapeutics (EIDX), Agios Pharmaceuticals (AGIO), OPKO Health (OPK), Pacira BioSciences (PCRX), Atea Pharmaceuticals (AVIR), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "medical" sector. Alkermes vs. Eidos Therapeutics Agios Pharmaceuticals OPKO Health Pacira BioSciences Atea Pharmaceuticals United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Eidos Therapeutics (NASDAQ:EIDX) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations. Does the media prefer EIDX or ALKS? In the previous week, Alkermes had 5 more articles in the media than Eidos Therapeutics. MarketBeat recorded 5 mentions for Alkermes and 0 mentions for Eidos Therapeutics. Alkermes' average media sentiment score of 1.30 beat Eidos Therapeutics' score of 0.00 indicating that Alkermes is being referred to more favorably in the news media. Company Overall Sentiment Eidos Therapeutics Neutral Alkermes Positive Do analysts prefer EIDX or ALKS? Alkermes has a consensus price target of $35.42, indicating a potential upside of 26.90%. Given Alkermes' stronger consensus rating and higher possible upside, analysts clearly believe Alkermes is more favorable than Eidos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eidos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alkermes 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58 Does the MarketBeat Community believe in EIDX or ALKS? Alkermes received 552 more outperform votes than Eidos Therapeutics when rated by MarketBeat users. Likewise, 70.51% of users gave Alkermes an outperform vote while only 63.20% of users gave Eidos Therapeutics an outperform vote. CompanyUnderperformOutperformEidos TherapeuticsOutperform Votes14663.20% Underperform Votes8536.80% AlkermesOutperform Votes69870.51% Underperform Votes29229.49% Which has preferable earnings and valuation, EIDX or ALKS? Alkermes has higher revenue and earnings than Eidos Therapeutics. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEidos Therapeutics$26.69M177.99-$37.83M-$1.03-118.65Alkermes$1.51B3.00$355.76M$1.9514.31 Is EIDX or ALKS more profitable? Alkermes has a net margin of 22.15% compared to Eidos Therapeutics' net margin of 0.00%. Alkermes' return on equity of 24.92% beat Eidos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eidos TherapeuticsN/A -65.21% -53.04% Alkermes 22.15%24.92%14.55% Which has more volatility & risk, EIDX or ALKS? Eidos Therapeutics has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Do insiders & institutionals have more ownership in EIDX or ALKS? 31.4% of Eidos Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 70.1% of Eidos Therapeutics shares are owned by insiders. Comparatively, 4.9% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryAlkermes beats Eidos Therapeutics on 16 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.45B$6.44B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio14.3110.78126.3217.81Price / Sales3.00243.711,179.2574.56Price / Cash12.4222.1633.8632.53Price / Book3.875.474.684.68Net Income$355.76M$153.61M$119.54M$226.08M7 Day Performance-1.55%-2.00%-1.83%-1.04%1 Month Performance0.72%-7.46%-3.60%1.04%1 Year Performance17.47%31.82%31.91%26.28% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.7788 of 5 stars$27.91+1.6%$35.42+26.9%+15.4%$4.45B$1.51B14.312,100Positive NewsEIDXEidos TherapeuticsN/A$122.21flatN/AN/A$4.75B$26.69M-118.6570AGIOAgios Pharmaceuticals3.3113 of 5 stars$54.62+0.4%$52.33-4.2%+154.0%$3.10B$32.87M4.81390OPKOPKO Health4.458 of 5 stars$1.58-2.5%$2.75+74.1%+6.8%$1.08B$863.50M-8.323,930PCRXPacira BioSciences4.1777 of 5 stars$17.03+1.8%$23.50+38.0%-38.5%$772.48M$674.98M0.00720Positive NewsAVIRAtea Pharmaceuticals2.7567 of 5 stars$3.16+0.6%$6.88+117.7%+5.0%$266.90M$351.37M-1.5370UTHRUnited Therapeutics4.5183 of 5 stars$364.33+1.0%$370.86+1.8%+59.1%$16.10B$2.33B16.001,168Positive NewsINCYIncyte3.9 of 5 stars$71.05+0.7%$77.16+8.6%+29.9%$13.69B$3.70B507.542,524Analyst ForecastNBIXNeurocrine Biosciences4.9503 of 5 stars$123.29+3.5%$163.91+32.9%+12.7%$12.06B$2.24B33.051,400Positive NewsBMRNBioMarin Pharmaceutical4.9885 of 5 stars$62.56+1.0%$94.20+50.6%-28.5%$11.92B$2.42B37.463,401EXELExelixis4.7765 of 5 stars$34.65+0.7%$31.44-9.3%+65.6%$9.90B$2.08B22.211,310Insider Trade Related Companies and Tools Related Companies Eidos Therapeutics Alternatives Agios Pharmaceuticals Alternatives OPKO Health Alternatives Pacira BioSciences Alternatives Atea Pharmaceuticals Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALKS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALKS Stock Alerts